Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jan;8(1):18-25.
doi: 10.1016/j.kisu.2017.10.005. Epub 2017 Dec 29.

Novel therapies for diabetic kidney disease

David Z I Cherney  1 , George L Bakris  2
Affiliations
Review

Novel therapies for diabetic kidney disease

David Z I Cherney et al. Kidney Int Suppl (2011). 2018 Jan.

Abstract

Over the past 30 years there have been many complementary therapies developed to achieve glycemic control and have an impact on cardiovascular outcomes, as well as reduce the risk of microvascular disease. The 2 most notable new entries have been the sodium-glucose cotransporter 2 (SGLT2) inhibitors and the glucagon-like peptide-1 (GLP-1) agonists. Both these classes of agents have demonstrated reductions in cardiovascular event rates as well as reductions in blood pressure and weight. Moreover, while both have demonstrated a benefit in slowing nephropathy progression, the SGLT2 inhibitors appear to have a significantly greater effect compared with the GLP-1 agents. There is an ongoing trial specifically powered for renal disease progression, CREDENCE (Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy). Additionally, there are 2 other classes of agents being tested to slow nephropathy progression, a selective endothelin-1 receptor antagonist, atrasantan, in the SONAR (Study of Diabetic Nephropathy With Atrasentan) trial and a nonsteroidal mineralocorticoid receptor antagonist, finerenone, in the FIDELIO (Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus) trial. These and other studies are discussed.

Keywords: SGLT2 inhibition; cardiovascular; diabetic kidney disease; endothelin; heart failure; incretin; inflammation; mineralocorticoid; uric acid.

PubMed Disclaimer

References

    1. Wong M.G., Perkovic V., Chalmers J. Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. Diabetes Care. 2016;39:694–700. - PubMed
    1. Lytvyn Y., Bjornstad P., Pun N. New and old agents in the management of diabetic nephropathy. Curr Opin Nephrol Hypertens. 2016;25:232–239. - PMC - PubMed
    1. Heerspink H.J., Perkins B.A., Fitchett D.H. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes: cardiovascular and kidney effects, potential mechanisms and clinical applications. Circulation. 2016;134:752–772. - PubMed
    1. Liakos A., Karagiannis T., Athanasiadou E. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16:984–993. - PubMed
    1. Vasilakou D., Karagiannis T., Athanasiadou E. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262–274. - PubMed

LinkOut - more resources